Overexpression of COX-2 and its products have been associated with various premalignant and malignant lesions of the gastrointestinal tract [22–24], and COX-2 has been posited as a potential biomarker for cancer risk and poor prognosis [24–27]. Here, PTGS2 is linked to cancer.